Gazelle delivers rapid laboratory-quality results to facilitate early detection
Beta thalassemia and sickle cell disease (SCD) are life-threatening,
genetic disorders that affect millions of people across the globe, many of whom could be helped with early testing. Gazelle enables affordable, convenient testing for newborns (SCD), patients, and marriage-age adults in at-risk population groups.
Gazelle reliably identifies and quantifies Hb A (normal), Hb S (sickle),
Hb F (fetal) and Hb A2/C/E. The device offers interpretative statements for beta thalassemia disease (intermedia and major) and trait (betathalassemia minor) as well as sickle cell disease and trait.